Joe Rogan Experience #782 - Rick Doblin

Episode Summary

Main Topics

Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), details the organization's three-decade effort to integrate psychedelic-assisted therapies into mainstream medicine, primarily focusing on MDMA for Post-Traumatic Stress Disorder (PTSD) and marijuana for various conditions. The conversation delves into the rigorous scientific and regulatory hurdles faced, the significant financial investment required for FDA approval, and the profound societal benefits, including mental health treatment, fostering human connection, and challenging the political origins of the War on Drugs. Doblin emphasizes the importance of data-driven research to overcome propaganda and establish these substances as legitimate therapeutic tools, highlighting the cultural shifts necessary for their widespread acceptance.

Key Discussion Points

• MDMA-Assisted Psychotherapy for PTSD: Doblin outlines MAPS's progress in submitting Phase 2 data to the FDA for MDMA-assisted psychotherapy for PTSD, aiming for Phase 3 studies projected to cost $245 million. He highlights the immense need, citing the VA's $6 billion annual spending on PTSD disability payments. The therapy involves three 8-hour MDMA sessions with a male-female co-therapist team in a clinical setting, focusing on memory reconsolidation and fear extinction by reducing amygdala activity. A novel study is also starting to administer MDMA to couples where one partner has PTSD, marking the first time two people will receive MDMA simultaneously in a modern research setting.
• Challenges of Psychedelic Research and Double-Blinding: A significant hurdle in psychedelic research is maintaining the double-blind standard, as participants usually know if they've received an active psychedelic or a placebo. Doblin explains MAPS's approach to this, involving a dose-response relationship where participants and therapists might be blind to the exact dosage received, using independent clinicians (CAPS scale) to objectively assess PTSD symptoms. He also shares a fascinating anecdote about the provenance of MAPS's original MDMA supply from 1985, produced by Dave Nichols, which, despite its purity, is not GMP-grade and needs to be replaced by a $400,000 batch for phase 3 studies, requiring a strict paper trail for all ingredients, down to aluminum foil.
• Marijuana Research and the Government Monopoly: Doblin details MAPS's long-standing struggle to conduct research on marijuana, specifically for PTSD in veterans. He explains the unique challenge of the federal government's monopoly on research marijuana through the University of Mississippi, controlled by the National Institute on Drug Abuse (NIDA), which historically provided low-potency strains and actively blocked independent research. MAPS has secured a $2.1 million Colorado grant for a 76-veteran PTSD study, testing various THC/CBD profiles, with the ultimate goal of FDA approval for the plant itself to enable insurance coverage.
• The Political Roots of the Drug War: The discussion touches upon the devastating and often overlooked political motivations behind the War on Drugs. Doblin references a quote by John Ehrlichman, a former Nixon aide, revealing that the administration intentionally criminalized drugs associated with anti-war hippies and civil rights-seeking Black communities to disrupt their movements, despite knowing the scientific exaggerations. This historical context underpins the ongoing difficulty in reclassifying substances like marijuana from Schedule I (no medical value, high abuse potential) to Schedule II (accepted medical use, high abuse potential).
• Psychedelics, Consciousness, and Societal Evolution: The episode explores the broader implications of psychedelic use beyond therapeutic applications, including their potential as "performance-enhancing" substances and tools for fostering connection and understanding. Doblin cites instances like athletes using marijuana, suggesting these substances can enhance focus and presence. He draws parallels between Albert Hofmann's discovery of LSD and the splitting of the atom, seeing both as powerful new "technologies"—one outer, one inner—necessary for a "new mode of thinking" to address global challenges. The conversation also explores the complex intersection of cultural appropriation and integration, such as Peruvian shamans bringing ayahuasca to treat addiction in Canadian First Nations communities, and the legal victories of religious groups like the UDV and Santo Daime in using ayahuasca.

Notable Moments

• Stoned Marathon Runner: Rick Doblin recounts running the New York Marathon while stoned, and midway through, stepping into a portapotty to smoke more marijuana to continue the race. He describes how pot helps him get into physical work and exercise.
• MDMA with Navajo Shamans: Doblin shares a unique experience of participating in an MDMA ceremony with Navajo shamans in their traditional language, mediated by a 17-year-old niece. He realized the ceremony was profoundly impactful for the niece, caught between two cultures, and highlighted the globalization of ideas even in remote communities.
• The "Junk Phase" of Writing: Rogan and Doblin connect over the challenges of creative work. Doblin recalls a Harvard professor who advised him to submit work in its "junk phase," acknowledging that creativity starts imperfectly. Rogan adds Earnest Hemingway's quote, "The first draft of everything is [expletive]," emphasizing the iterative nature of writing.

Key Takeaways

This episode uniquely highlights MAPS's steadfast, three-decade commitment to rigorously scientific, FDA-approved psychedelic research, particularly MDMA for PTSD, as the most viable path to mainstream acceptance. Listeners gain insight into the intricate regulatory and financial challenges of bringing a Schedule I drug to market, including the unprecedented cost of Phase 3 trials and the unique hurdles of government-controlled marijuana for research. The discussion powerfully connects the personal, therapeutic benefits of psychedelics to broader societal shifts, arguing that their potential to foster empathy and self-acceptance can help navigate global challenges, while challenging the historical, political motivations of drug prohibition. It underscores the profound impact of data-driven advocacy in changing public perception and policy, offering a hopeful vision for the future of mental health and human connection.